Press Release<< Back
Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin
-- MAA submission for complicated urinary tract infections (cUTI), bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment options --
- Complicated urinary tract infections (cUTI), including pyelonephritis,
- Bloodstream infections (BSI) due to certain Enterobacteriaceae and
- Infections due to Enterobacteriaceae in adult patients with limited treatment options
Plazomicin is marketed as ZEMDRI™ in
"Our mission is to bring much-needed antibiotics to patients globally and, with this MAA submission, we are one step closer to that goal,” said Blake Wise, Achaogen’s Chief Executive Officer. “We look forward to the acceptance of this application and the potential to bring a new treatment option to EU patients and healthcare professionals who face the daily challenge of treating recurrent and resistant gram-negative infections.”
The MAA is supported by data from both the EPIC (Evaluating Plazomicin In cUTI) and
cUTI is defined as a urinary tract infection occurring in a patient with an underlying complicating factor of the genitourinary tract, such as a structural or functional abnormality.1 Patients with pyelonephritis, regardless of underlying abnormalities of the urinary tract, are considered a subset of patients with cUTI.2 An estimated 3.5 million cases of cUTI are treated in the hospital setting in the EU-5 each year.3 Enterobacteriaceae are the most common pathogens causing cUTIs4, and resistance within this family is a global concern. High rates of resistance to previous mainstays of therapy necessitate alternative treatment options. Ineffectively managed cUTI can lead to increased treatment failure rates, recurrence of infection, increased re-hospitalization, and increased morbidity and mortality. cUTI infections place an economic burden on hospitals and payers.4,5
About Multi-Drug Resistant (MDR) Gram-Negative Infections
Multidrug resistant gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE), are a type of gram-negative bacteria with resistance to multiple antibiotics. They can cause bacterial infections that pose a serious threat for hospitalized patients. The lack of availability of medicines to treat patients with infections caused by resistant bacteria has become a major problem in recent years. It is estimated that at least 25,000 patients in the
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential uses and advantages of ZEMDRI, Achaogen commercial objectives and the Achaogen pipeline of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Achaogen's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Achaogen business in general, see Achaogen current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 27, 2018, and its Quarterly Report on Form 10-Q filed on
Investor and Media Contact:
1Nicolle LE. J Infect Dis. 2001;183(Suppl 1):S5-8.
2U.S. Food & Drug. Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry.https://www.fda.gov/downloads/Drugs/Guidances/ucm070981.pdf. Accessed
3Decision Resources Disease Epidemiology 2017.
4Bader MS et al. Postgrad Med. 2010;122(6):7-15.
5Turner RM et al.
6Information Session on Antibiotic Resistance held by EMA,
Source: Achaogen, Inc.